Abstract
Patient characteristics that increase the risk of continuous-flow left ventricular assist device thrombosis have not been well established. We report a case of HeartWare thrombosis in a patient with aspirin hyporesponsiveness, and discuss the role of platelet function testing in preventing this severe complication. There is a need for clinical trials determining optimal antiplatelet therapy in patients supported with left ventricular assist devices, and consensus regarding modification of antiplatelet therapy after device thrombosis.
Keywords:
Aspirin; drug resistance; heart-assist devices; platelet aggregation; thromboembolism.
MeSH terms
-
Aged
-
Aspirin / therapeutic use*
-
Cardiomyopathy, Dilated / diagnosis
-
Cardiomyopathy, Dilated / physiopathology
-
Cardiomyopathy, Dilated / therapy*
-
Clopidogrel
-
Drug Resistance*
-
Drug Substitution
-
Fibrinolytic Agents / therapeutic use*
-
Heart Valve Prosthesis / adverse effects*
-
Humans
-
International Normalized Ratio
-
Male
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prosthesis Design
-
Thrombolytic Therapy
-
Thrombosis / blood
-
Thrombosis / diagnosis
-
Thrombosis / drug therapy
-
Thrombosis / etiology*
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
-
Treatment Outcome
-
Ventricular Function, Left*
Substances
-
Fibrinolytic Agents
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine
-
Aspirin